Keith Millar
CEO
C
CryoStasis
Shutdowncryostasis.ca
Website unreachable since Oct 31, 2026
The startup develops a cryopreservation system that utilizes proprietary cold shock inhibitors and membrane protectants to prevent cryoinjury to biological materials. This technology ensures precise control over storage conditions, enabling biotech companies and researchers to preserve biological samples effectively for therapeutic and scientific applications.
- Biotechnology
Updated 6 months ago
Funding
Raised to date
$8MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Problem
Current methods of preserving biological materials, such as cells, tissues, and organs, often rely on freezing, which can cause cryoinjury and reduce viability. Existing preservation protocols and solutions have seen limited innovation in the past 50 years, leading to suboptimal clinical outcomes and high unmet medical needs in organ transplantation and cell/gene therapies.
Solution
CryoStasis has developed a biopreservation platform, called Woolii™ SU, that enables the subzero unfrozen storage of biological material to maintain optimal cell viability and function. The platform uses a novel cold chain management process that combines proprietary media, temperature, and pressure controls to preserve biological material indefinitely. The media leverages cold shock inhibitors and membrane protectants to prevent cryoinjury to cells. The temperature systems include devices and shipping solutions to ensure viability and seamless integration into manufacturing and logistics. The pressure systems lower the freezing point and cell metabolism, enabling long-term storage.
Target Audience
The primary customers are doctors, researchers, and companies in the healthcare and research industry, specifically those involved in cell and gene therapy, regenerative medicine, and organ transplantation.
Features
- Woolii™ SU platform for subzero unfrozen cell preservation
- Proprietary media formulation that is serum-free, DMSO-free, and chemically defined
- Media leverages cold shock inhibitors and membrane protectants to prevent cryoinjury
- Temperature systems with devices and shipping solutions for maintaining viability during transport and storage
- Pressure systems to lower the freezing point and cell metabolism for long-term storage
- Ambient Pressure Sub-Zero Unfrozen (APSU) solution for short-term storage and shipping up to a week
- High Pressure Sub-Zero Unfrozen (HPSU) solution for inducing suspended animation and indefinite storage
- Quality Management System built on ISO 13485, ISO 14971, and FDA’s 21 CFR Part 820